Neurenati Therapeutics Inc.’s NEU-001 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Hirschsprung disease.
Just over a year since the last anti-nerve growth factor (NGF) antibody program was axed, the target is poised for a revival, with Levicept Ltd. announcing it has completed recruitment to a phase II trial of LEVI-04 in the control of chronic pain caused by osteoarthritis.
A deficiency in neurotrophic factor signaling has been shown to exacerbate environmental risk factors for the development of Alzheimer's disease pathogenesis in mice, according to a study reported in the June 22, 2021, online edition of the Proceedings of the National Academy of Sciences.
